NICE Enough? Watchdog's Basic Approach Is Sound, But More Transparency Is Urged
This article was originally published in The Pink Sheet Daily
Executive Summary
An independent report into how NICE values medicines concludes that the basis of its cost-effectiveness assessment is sound, but can be improved. And more transparency would help.
You may also be interested in...
NICE Likely To Lose Cost-Watchdog Status By 2013
The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.
NICE To Lose Cost Watch-dog Status By 2013
The National Institute for Health and Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to UK ministers speaking in London on October 25. Instead, a new value-based pricing system will see drug prices set to reflect a product's worth in the first place, without the need for NICE to carry out its assessment once a drug is already available.News of an end to NICE's most controversial activity will be welcomed by the many companies that have seen their products' commercial potential in the UK severely limited by a negative assessment from the cost watchdog - even though details of the alternative, value-based pricing, are far from clear.
NICE Likely To Lose Cost-Watchdog Status By 2013
The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.